Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 05, 2022

SELL
$2.27 - $4.86 $416,642 - $892,018
-183,543 Reduced 78.68%
49,723 $138,000
Q1 2022

May 12, 2022

SELL
$3.69 - $5.65 $793,619 - $1.22 Million
-215,073 Reduced 47.97%
233,266 $1.02 Million
Q4 2021

Feb 10, 2022

BUY
$5.37 - $7.07 $5,917 - $7,791
1,102 Added 0.25%
448,339 $2.48 Million
Q3 2021

Nov 12, 2021

BUY
$5.54 - $7.51 $1.57 Million - $2.13 Million
283,833 Added 173.7%
447,237 $2.76 Million
Q2 2021

Aug 12, 2021

BUY
$7.78 - $11.4 $144,241 - $211,356
18,540 Added 12.8%
163,404 $1.39 Million
Q1 2021

May 13, 2021

BUY
$5.12 - $8.48 $620,723 - $1.03 Million
121,235 Added 513.08%
144,864 $1.15 Million
Q4 2020

Feb 16, 2021

BUY
$3.16 - $7.03 $74,667 - $166,111
23,629 New
23,629 $138,000
Q2 2020

Aug 13, 2020

SELL
$1.58 - $4.63 $82,316 - $241,218
-52,099 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$1.44 - $3.02 $37,078 - $77,761
25,749 Added 97.72%
52,099 $82,000
Q4 2019

Feb 12, 2020

SELL
$2.25 - $3.07 $3,150 - $4,298
-1,400 Reduced 5.05%
26,350 $72,000
Q3 2019

Nov 13, 2019

SELL
$2.67 - $3.65 $82,775 - $113,157
-31,002 Reduced 52.77%
27,750 $82,000
Q2 2019

Aug 07, 2019

BUY
$2.6 - $4.21 $152,755 - $247,345
58,752 New
58,752 $169,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.